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Case report
Eosinophilic fasciitis presenting as psoriatic
arthropathy
G D Wright, Claire Thornton, D A J Keegan, A L Bell
Accepted 28 January 1992.
We describe a patient with eosinophilic fasciitis, a rare scleroderma -like steroid -
responsive condition. Initial presentation suggested pauciarticular psoriatic
arthritis.
CASE HISTORY. A 19-year-old student nurse presented with a four month
history of pain and stiffness in her knees, ankles and elbows following a brief
'flu-like illness. Wrist and elbow movements were limited, with bilateral knee
effusions and flexion deformities ofapproximately 100. Evidence ofpsoriasis was
limited to areas of hyperkeratosis on the elbows, and a few nail pits; there was
a positive history in her maternal grandmother. Rheumatoid factor test was
negative, serum C-reactive protein 19-5 mg/I (normal <6), and erythrocyte
sedimentation rate 39 mm/hr. X-rays of hands, elbows and knees were normal.
A provisional diagnosis of psoriatic arthropathy was made and she was treated
with the nonsteroidal anti-inflammatory drug nabumetone 1 gm daily, with
improvement.
Five months later her condition deteriorated, her skin felt "very tight", and
she had to walk on her toes because of tightness at the ankle. She described
occasional difficulty with swallowing but gave no history of Raynaud's phen-
omenon. She now had thickened, shiny skin on the limbs and flexion deformity
of her knees, wrists, and the small joints in her hands. Systemic sclerosis was
considered tobethelikely diagnosis, and shewascommenced on d -penicillamine
100 mg/day and nifedipine 10 mg/tid.
Investigations showed eosinophilia of 8%; ESR 32 mm; C-reactive protein
< 6 mg/I; serum IgM 2-72 g/l. Relevant autoantibody tests were negative
(including antinuclear factor, anti-centromere antibody, anti SCL-70 and anti-
neutrophil cytoplasmic antibody); complement components were normal and
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circulating immune complexes were not detected (Clq binding). Isotope bone
scan revealed synovitis in both wrists, the metacarpophalangeal joints of both
hands and ankles. Borrelia burgdorferi titres were negative. Barium swallow was
normal.
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Figure. Thickened dermis and hyaliniz-
ation of collagen bundles with chronic
inflammatory cell infiltrate.
Full thickness skin biopsy showed an intact
epidermis, without hyperkeratosis or follic-
ular plugging, and there was no vacuolar
degeneration of the basal layer. There was
loss of hair follicles, and the skin appendage
structures were small and atrophic. The
papillary dermis and upper reticular dermis
wererelativelynormal but thedeeperdermis
showed thickened hyalinized eosinophilic
collagen fibres (Figure). The dermis
appeared thickened andtherewasextension
of the collagen into the underlying subcutis.
The fibrous septa within the subcutaneous
fat were widened and within the fibrous
tissuethere werescattered chronicinflamm-
atory cells at the periphery of the lobules of
fat. The infiltrate was composed predomin-
antly of lymphocytes and plasma cells with
scattered histiocytes, but no eosinophils.
The fascia was thickened, homogeneous
and eosinophilic and was permeated by a
chronic inflammatory cell infiltrate. A little
ujnerilrvina skplptal miiusrl wua nresnt in
the biopsy and this showed myofibril degeneration and interstitial fibrosis. The
overall appearances were those of eosinophilic fasciitis (Shulman's syndrome).
Following histological diagnosis she was commenced on hydroxychloroquine
sulphate 200 mg/day, prednisolone 40 mg/day and cimetidine 400 mg/twice
daily; d-penicillamine was discontinued. She made a slow but gradual improve-
ment, with return to normal gait.
It has been necessary to continue steroids at a relatively high dose.
DISCUSSION
Over 200 cases of eosinophilic fasciitis have been described since the initial
description by Shulman.' It is a scleroderma - like disease characterised by
symmetrical widespread inflammation and sclerosis of the deep fascia, sub. cutis
and dermis: it has been termed morphoea profunda by some authors. It primarily
involvesthe extremities, andisassociated withperipheral bloodand tissue eosino -
philia, and often hypergammaglobulinaemia. Although well described, onsetwith
polyarthritis may lead to initial diagnostic difficulty. Synovitis of large joints,
hyperkeratosis and nail pits in conjunction with a family history of psoriasis, is a
common mode of presentation ofthe pauciarticular type of psoriatic arthritis, and
we believe this is the first report ofeosinophilic fasciitis presenting in this manner.
Synovitis had been present for at least four months prior to the insidious onset of
sclerotic skin changes.
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Eosinophilic fasciitis may be part of the spectrum of systemic sclerosis, as after
one or two years a proportion of patients develop chronic fibrotic cutaneous
features and some develop systemic manifestations, but there are some signific-
ant differences. These include the relative absence of Raynaud's phenomenon,
normal nailfold capillary microscopy,2 sparing of the epidermis and dermis,
infrequent visceral involvement, absence of the serological features which
characterise systemic sclerosis and the rare development of haematological
complications.3 The male to female ratio is approximately equal, and in a recent
review of 52 patients at the Mayo Clinic4 the mean age of onset was 47 years. In
46% of these cases, onset was related to unaccustomed strenuous exertion.
Some authors mention a prodromal febrile illness as described by our patient,
perhaps suggesting a viral trigger factor.5 Cutaneous manifestations are usual
presenting features, and evolve through three stages: pitting oedema at onset,
peau d'orange or dimpling, and finally induration. The most common sites are
the arms and legs, with infrequent involvement of hands and feet. Isolated cases
of oesophageal, cardiac or pulmonary disease have been described, but in
contrast to systemic sclerosis these are uncommon features. In over 60% of
cases eosinophilia is greater than 7% of the total white cell count, although
peripheral eosinophilia can be transient, even in the absence of corticosteroid
treatment. In our patient, eosinophilia was detected only once in her year.-long
illness.
To confirm the diagnosis a deep skin biopsy, including tissue from the epidermis
down totheskeletal musclethrough thedeep fascia, must beperformed. Changes
range from inflammation with minimal connective tissue change to severe
sclerosis. The deep fascia and septa of the subdermal fat are most extensively
involved while the epidermis is normal oronly slightly atrophic. Despite the name,
the presence of eosinophils in the inflammatory infiltrate is not required for
diagnosis. It is essentially a corticosteroid
- responsive benign condition but
patients with chronic ongoing disease have been described. In the larger
proportion of cases resolution, which may be spontaneous, occurs within five
years. Relapses, although unusual, do occur. Our patient displayed a character-
istic clinical response to prednisolone. Cimetidine has also been reported to be
effective,6'7 perhaps by involving the capacity of H2 receptor antagonists to
interfere with suppressor T-cell control.8
The etiology of eosinophilic fasciitis is unknown. One report of the condition
developing in siblings not recently in contact within six months suggests the
influence of genetic factors: they shared HLA A,B,C,DR, and DQ antigens.9
Hypersensitivity reactions to muscle tissue following exercise-induced damage
and an association with cancer have also been demonstrated. An unusual
syndrome characterised by incapacitating myalgia and peripheral eosinophilia in
patients taking L-tryptophan has recently been reported. Some of these patients
developed sclerotic cutaneous changes and the condition has been termed the
eosinophilia myalgia syndrome. Overlapping clinical features suggested a relat-
ionship of both these syndromes with the toxic oil syndrome, a multi-system
disease associated with ingestion of adulterated cooking oil in Spain in 1981.
Although these three conditions display many features in common, Shulman'0
described distinguishing clinical and laboratory features. Polyarthritis appeared to
be equally prevalent in all three conditions. The recent suggestion that Borrelia
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burgdorferi infections may be responsible for scieroderma variants including
eosinophilic fasciitis remains speculative.11
This case illustrates the need for precise diagnosis in patients who present with
inflammatory polyarthritis and cutaneous sclerosis. Systemic sclerosis is unres-
ponsive to steroids and the prognosis is often poor. In contrast, patients with
eosinophilic fasciitis respond well to steroids or other potent immunosuppressive
therapy and complete remission may occur. Appropriate full-thickness skin
biopsy must beconsidered inall patientswith clinically atypical systemic sclerosis.
We thank Mr C J F Russell, FRCS (Royal Victoria Hospital) for the tissue biopsy and Mrs M Maguire for
typing the manuscript.
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